US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Abivax S.A.

6.71

-0.1400-2.04%

Post-market: 6.710.00000.00%16:00 EDT

Volume:17.24K

Turnover:116.97K

Market Cap:425.46M

PE:-2.32

High:6.99

Open:6.98

Low:6.66

Close:6.85

Loading ...

Overview Company News Filings

Abivax publishes financial reports with the French and U.S. securities regulatory agencies

Abivax FY24 Net loss Stood At €(176.2)M Vs. €(147.8)M In FY23

Abivax Cash Position Stood At €144M As Of December 31, 2024

Abivax SA expected to post a loss of 68 cents a share - Earnings Preview

Abivax SA Sponsored ADR (ABVX) Gets a Buy from Piper Sandler

Piper Sandler Sticks to Their Buy Rating for Abivax SA Sponsored ADR (ABVX)

Morgan Stanley Sticks to Its Hold Rating for Abivax SA Sponsored ADR (ABVX)

Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn’s and Colitis Organization 20th Annual Congress

Analysts Offer Insights on Healthcare Companies: IGM Biosciences (IGMS) and Abivax SA Sponsored ADR (ABVX)

Abivax Reaches 82% Enrollment in Phase 3 Ulcerative Colitis Trial

MT Newswires Live

Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment

Abivax Announces A Change To The Composition Of Its Board Of Directors

Abivax SA Sponsored ADR (ABVX) Gets a Buy from JMP Securities

Stock Track | Abivax Soars 5.54% as Analyst Initiates Coverage with Bullish Outlook

JMP Securities Initiates Abivax at Market Outperform With $33 Price Target

MT Newswires Live

Abivax Initiates $150 Million ATM Program on Nasdaq

Abivax Q3 Total Principal Debt Outstanding €106.3M Down From €108.4M YoY

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ABVX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ABVX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ABVX\",,,,,undefined,":{"symbol":"ABVX","market":"US","secType":"STK","nameCN":"Abivax S.A.","latestPrice":6.71,"timestamp":1746820800000,"preClose":6.85,"halted":0,"volume":17236,"hourTrading":{"tag":"盘后","latestPrice":6.71,"preClose":6.71,"latestTime":"16:00 EDT","volume":9,"amount":60.39,"timestamp":1746820807672},"delay":0,"floatShares":32031588,"shares":63407318,"eps":-2.894125,"marketStatus":"Market Closed","change":-0.14,"latestTime":"05-09 16:00:00 EDT","open":6.98,"high":6.99,"low":6.655,"amount":116974.6118,"amplitude":0.048905,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.894125,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1747036800000},"marketStatusCode":7,"adr":0,"adrRate":1,"listingDate":1697774400000,"exchange":"NASDAQ","adjPreClose":6.85,"postHourTrading":{"tag":"盘后","latestPrice":6.71,"preClose":6.71,"latestTime":"16:00 EDT","volume":9,"amount":60.39,"timestamp":1746820807672},"volumeRatio":0.1734628769717866},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ABVX\",,,,,undefined,":{"symbol":"ABVX","floatShares":32031588,"roa":"-40.62%","roe":"-148.98%","lyrEps":-2.894125,"volumeRatio":0.1734628769717866,"shares":63407318,"dividePrice":0,"high":6.99,"amplitude":0.048905,"preClose":6.85,"low":6.655,"week52Low":4.77,"pbRate":"9.32","psRate":"35.04","week52High":14.72,"institutionHeld":0,"latestPrice":6.71,"eps":-2.894125,"divideRate":0,"volume":17236,"delay":0,"ttmEps":-2.894125,"open":6.98,"prevYearClose":7.32,"prevWeekClose":7.19,"prevMonthClose":7.12,"prevQuarterClose":6.25,"fiveDayClose":7.19,"twentyDayClose":5.59,"sixtyDayClose":6.8,"earningDate":1748793600000,"earningTime":"盘后"},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ABVX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2522356175","title":"Abivax publishes financial reports with the French and U.S. securities regulatory agencies","url":"https://stock-news.laohu8.com/highlight/detail?id=2522356175","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522356175?lang=en_us&edition=fundamental","pubTime":"2025-03-27 05:05","pubTimestamp":1743023100,"startTime":"0","endTime":"0","summary":"PARIS, France – March 26, 2025 – 10:05 PM CET – Abivax SA  , a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, announces the filing of its Universal Registration Document  with the French Financial Market Authorities, Autorité des Marchés Financiers , and the filing of its Annual Report  with the U.S. Securities and Exchange Commission  on March 24, 2025.The Universal Registration Document includes the 2024 annual financial report, the management report including the report on corporate governance, as well as the reports of the statutory auditors.Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Based in France and the United States, Abivax’s lead drug candidate, ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/abivax-publishes-financial-reports-french-210500560.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ABVX","BK4139","AAVXF"],"gpt_icon":0},{"id":"2521762826","title":"Abivax FY24 Net loss Stood At €(176.2)M Vs. €(147.8)M In FY23","url":"https://stock-news.laohu8.com/highlight/detail?id=2521762826","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521762826?lang=en_us&edition=fundamental","pubTime":"2025-03-24 15:39","pubTimestamp":1742801960,"startTime":"0","endTime":"0","summary":"Abivax FY24 Net loss Stood At €(176.2)M Vs. €(147.8)M In FY23","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44452526/abivax-fy24-net-loss-stood-at-176-2-m-vs-147-8-m-in-fy23","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ABVX"],"gpt_icon":0},{"id":"2521762830","title":"Abivax Cash Position Stood At €144M As Of December 31, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2521762830","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521762830?lang=en_us&edition=fundamental","pubTime":"2025-03-24 15:36","pubTimestamp":1742801814,"startTime":"0","endTime":"0","summary":"Abivax Cash Position Stood At €144M As Of December 31, 2024","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44452503/abivax-cash-position-stood-at-144m-as-of-december-31-2024","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX","BK4139"],"gpt_icon":0},{"id":"2521157235","title":"Abivax SA  expected to post a loss of 68 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2521157235","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521157235?lang=en_us&edition=fundamental","pubTime":"2025-03-21 23:02","pubTimestamp":1742569345,"startTime":"0","endTime":"0","summary":"Abivax SA  expected to post a loss of68cents a share - Earnings Preview Abivax SA ABVX.OQ, ABVX.O is expected to report resultson March 24 for the period ending September 30 2024The Paris Ile-de-franc","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250321:nL8N3Q41IA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"gpt_icon":0},{"id":"2518480432","title":"Abivax SA Sponsored ADR (ABVX) Gets a Buy from Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2518480432","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518480432?lang=en_us&edition=fundamental","pubTime":"2025-03-10 17:45","pubTimestamp":1741599918,"startTime":"0","endTime":"0","summary":"Piper Sandler analyst Allison Bratzel maintained a Buy rating on Abivax SA Sponsored ADR (ABVX – Research Report) on March 7 and set a price target...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/abivax-sa-sponsored-adr-abvx-gets-a-buy-from-piper-sandler?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/abivax-sa-sponsored-adr-abvx-gets-a-buy-from-piper-sandler?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AAVXF","BK4139","ABVX"],"gpt_icon":0},{"id":"2510774853","title":"Piper Sandler Sticks to Their Buy Rating for Abivax SA Sponsored ADR (ABVX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2510774853","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510774853?lang=en_us&edition=fundamental","pubTime":"2025-02-10 19:45","pubTimestamp":1739187952,"startTime":"0","endTime":"0","summary":"Piper Sandler analyst Christopher Raymond maintained a Buy rating on Abivax SA Sponsored ADR (ABVX – Research Report) today and set a price target ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/piper-sandler-sticks-to-their-buy-rating-for-abivax-sa-sponsored-adr-abvx?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/piper-sandler-sticks-to-their-buy-rating-for-abivax-sa-sponsored-adr-abvx?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ABVX","AAVXF"],"gpt_icon":0},{"id":"2506518788","title":"Morgan Stanley Sticks to Its Hold Rating for Abivax SA Sponsored ADR (ABVX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2506518788","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506518788?lang=en_us&edition=fundamental","pubTime":"2025-01-28 20:56","pubTimestamp":1738068997,"startTime":"0","endTime":"0","summary":"In a report released today, Vikram Purohit from Morgan Stanley maintained a Hold rating on Abivax SA Sponsored ADR (ABVX – Research Report), with a...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/morgan-stanley-sticks-to-its-hold-rating-for-abivax-sa-sponsored-adr-abvx?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":"a4f53057487a84b640754ed046ea1dd3","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/morgan-stanley-sticks-to-its-hold-rating-for-abivax-sa-sponsored-adr-abvx?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ABVX","AAVXF"],"gpt_icon":0},{"id":"2505293100","title":"Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn’s and Colitis Organization 20th Annual Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2505293100","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505293100?lang=en_us&edition=fundamental","pubTime":"2025-01-24 05:05","pubTimestamp":1737666300,"startTime":"0","endTime":"0","summary":"Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn’s and Colitis Organization 20th Annual Congress. PARIS, France – January 23, 2025 – 10:05 PM CET – Abivax SA  , a clinical-stage biotechnology company developing innovative therapies to address chronic inflammatory diseases, today announced that seven scientific abstracts on its lead drug candidate, obefazimod, [an investigational, orally administered, once-daily small molecule] in clinical development for the treatment of moderately to severely active ulcerative colitis , will be presented at The European Crohn’s and Colitis Organization’s  20th Annual Congress as part of scientific exchange, taking place February 19-22, 2025, in Berlin, Germany.“With 7 abstracts accepted for presentation at ECCO 2025, we look forward to our continued exchange with the inflammatory bowel disease community around the emerging clinical profile of obefazimod,” said Fabio Cataldi, MD, Chief Medical","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/abivax-announces-presentation-seven-abstracts-210500730.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ABVX","AAVXF","BK4139"],"gpt_icon":0},{"id":"2502857293","title":"Analysts Offer Insights on Healthcare Companies: IGM Biosciences (IGMS) and Abivax SA Sponsored ADR (ABVX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2502857293","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502857293?lang=en_us&edition=fundamental","pubTime":"2025-01-10 20:30","pubTimestamp":1736512213,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on IGM Biosciences (IGMS – Research Report) and Abiva...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-igm-biosciences-igms-and-abivax-sa-sponsored-adr-abvx?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-igm-biosciences-igms-and-abivax-sa-sponsored-adr-abvx?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4505","ABVX","AAVXF","BK4137","IGMS","IGM","HCSG","BK4139"],"gpt_icon":0},{"id":"2502102699","title":"Abivax Reaches 82% Enrollment in Phase 3 Ulcerative Colitis Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2502102699","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502102699?lang=en_us&edition=fundamental","pubTime":"2025-01-10 03:26","pubTimestamp":1736450794,"startTime":"0","endTime":"0","summary":"Abivax  said Thursday that it reached 82% of target enrollment in a phase 3 trial evaluating obefazimod for the treatment of moderately to severely active ulcerative colitis.Enrollment stood at 1,003 of 1,224 targeted participants and is expected to be completed in Q2, according to the biotechnology company.The company's cash runway will extend beyond the trial readout and into Q4, Abivax said.Price: 6.68, Change: -0.30, Percent Change: -4.30","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ABVX","BK4139"],"gpt_icon":0},{"id":"2502044565","title":"Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment","url":"https://stock-news.laohu8.com/highlight/detail?id=2502044565","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502044565?lang=en_us&edition=fundamental","pubTime":"2025-01-10 00:35","pubTimestamp":1736440500,"startTime":"0","endTime":"0","summary":"Phase 3 ABTECT Trial evaluating obefazimod for moderately to severely active ulcerative colitis  reaches 1,003 of 1,224 participants, representing 82% of target enrollment. Enrollment completion expected in Q2 2025.Blinded baseline characteristics align with pre-specified target population and consistent with Phase 2b UC trial. Marc de Garidel, Chief Executive Officer of Abivax, commented:“We are thrilled to announce that the ABTECT Phase 3 trial has reached a significant milestone, with over 1,000 participants enrolled, representing 82% of our targeted enrollment. This progress underscores the enthusiasm of investigators and patients for this important trial, which remains among the fastest-enrolling Phase 3 UC trials to date.”Mr. de Garidel went on to say, “In order to ensure a balanced representation of bio-nave and bio-experienced participants amid heightened competition in UC trial recruitment, we now anticipate completing enrollment in Q2 2025 and delivering top-line results for ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/abivax-achieves-key-milestone-phase-163500976.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ABVX","AAVXF","BK4139"],"gpt_icon":0},{"id":"2493706845","title":"Abivax Announces A Change To The Composition Of Its Board Of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2493706845","media":"T-Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493706845?lang=en_us&edition=fundamental","pubTime":"2024-12-24 05:36","pubTimestamp":1734989779,"startTime":"0","endTime":"0","summary":"Abivax SA :Abivax Announces A Change To The Composition Of Its Board Of Directors.Abivax Sa - Representative Of Truffle Capital, Philippe Pouletty,  Resigns As Director.Abivax Sa: Pouletty'S Decision Directly Related To His Appointment Last Week As Chairman And Acting Ceo Of A  Biotechnology Co.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.trkd.thomsonreuters.com","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ABVX"],"gpt_icon":0},{"id":"2489469847","title":"Abivax SA Sponsored ADR (ABVX) Gets a Buy from JMP Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2489469847","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489469847?lang=en_us&edition=fundamental","pubTime":"2024-12-05 23:55","pubTimestamp":1733414102,"startTime":"0","endTime":"0","summary":"JMP Securities analyst Jason Butler initiated coverage with a Buy rating on Abivax SA Sponsored ADR (ABVX – Research Report) yesterday and set a pr...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/abivax-sa-sponsored-adr-abvx-gets-a-buy-from-jmp-securities-3?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/abivax-sa-sponsored-adr-abvx-gets-a-buy-from-jmp-securities-3?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","JMP","BK4127","AAVXF","ABVX"],"gpt_icon":0},{"id":"1165684470","title":"Stock Track | Abivax Soars 5.54% as Analyst Initiates Coverage with Bullish Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=1165684470","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1165684470?lang=en_us&edition=fundamental","pubTime":"2024-12-05 00:18","pubTimestamp":1733329098,"startTime":"0","endTime":"0","summary":"Shares of Abivax S.A.  rallied 5.54% in Wednesday's intraday trading session, following a positive initiation note from an analyst. The biopharmaceutical company's stock surged after JMP Securities initiated coverage with an Outperform rating and a price target of $33, reflecting significant upside potential from current levels.According to the analyst, Abivax's pipeline, including its lead candidate for ulcerative colitis and other inflammatory bowel diseases, presents a promising opportunity. ","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Stock Track | Abivax Soars 5.54% as Analyst Initiates Coverage with Bullish Outlook","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["ABVX"],"gpt_icon":0},{"id":"2488516082","title":"JMP Securities Initiates Abivax at Market Outperform With $33 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2488516082","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488516082?lang=en_us&edition=fundamental","pubTime":"2024-12-04 20:32","pubTimestamp":1733315520,"startTime":"0","endTime":"0","summary":"Abivax SA (ABVX) has an average rating of buy and mean price target of $32.44, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ABVX","JMP"],"gpt_icon":0},{"id":"2484014819","title":"Abivax Initiates $150 Million ATM Program on Nasdaq","url":"https://stock-news.laohu8.com/highlight/detail?id=2484014819","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484014819?lang=en_us&edition=fundamental","pubTime":"2024-11-20 05:59","pubTimestamp":1732053541,"startTime":"0","endTime":"0","summary":"Abivax SA Sponsored ADR (ABVX) has released an update. Abivax has launched an At-The-Market (ATM) program on Nasdaq, allowing the company to raise ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/abivax-initiates-150-million-atm-program-on-nasdaq?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/abivax-initiates-150-million-atm-program-on-nasdaq?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4112","NDAQ","QLD","BK4585","MNQmain","IE00BGHQF748.EUR","IE00B64PRP62.GBP","TQQQ","BK4139","NQmain","LU2210150020.SGD","QID","PSQ","IE00B3QW5Z07.USD","LU2210149790.SGD","SQQQ",".IXIC","ABVX","LU2095319765.USD","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2483824356","title":"Abivax Q3 Total Principal Debt Outstanding €106.3M Down From €108.4M YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2483824356","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483824356?lang=en_us&edition=fundamental","pubTime":"2024-11-15 06:12","pubTimestamp":1731622341,"startTime":"0","endTime":"0","summary":"Abivax Q3 Total Principal Debt Outstanding €106.3M Down From €108.4M YoY","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/41993398/abivax-q3-total-principal-debt-outstanding-106-3m-down-from-108-4m-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX","BK4534","BK4585","TSS","BK4566","PFG","LU1989772840.SGD","BK4162","LU1989772923.USD","BK4139","BK4588"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":17,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ABVX\",params:#limit:5,,,undefined,":[{"date":"2025-06-02","symbol":"ABVX","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1748894400000,"name":null,"time":"Post Market","dateTimestamp":1748836800000,"actualEps":null},{"date":"2025-03-24","symbol":"ABVX","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2024/12","expectedEps":-0.67,"defaultRemindTime":1742803200000,"name":null,"time":"Pre-Market","dateTimestamp":1742788800000,"actualEps":null},{"market":"US","date":"2024-11-14","symbol":"ABVX","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731560400000,"reportTimeType":"post","actualEps":null},{"date":"2024-09-09","symbol":"ABVX","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1725868800000,"name":null,"time":"Pre-Market","dateTimestamp":1725854400000,"actualEps":null},{"market":"US","date":"2024-04-02","symbol":"ABVX","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1712030400000,"reportTimeType":"","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ABVX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ABVX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.5,"hold":0.1667,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5,"analysts":6,"updateTime":1733371200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ABVX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ABVX","date":"2025-05-09","current":-2.219807,"percent":0.862637,"low":-9.732151,"twenty":-6.744484,"median":-4.599123,"eighty":-2.430392,"high":-0.02231,"avg":-4.771537,"sd":2.253147,"marketCap":441113036.42},"quantilePoints":[{"date":"2023-10-27","current":-7.823172,"twenty":-7.328793,"median":-6.587224,"eighty":-5.845656,"marketCap":753894810.45},{"date":"2023-11-03","current":-6.291292,"twenty":-6.250217,"median":-6.06538,"eighty":-6.010614,"marketCap":611163613.59},{"date":"2023-11-10","current":-6.503512,"twenty":-6.645905,"median":-6.346058,"eighty":-6.06538,"marketCap":637532258.17},{"date":"2023-11-17","current":-7.092251,"twenty":-6.941614,"median":-6.503512,"eighty":-6.069488,"marketCap":704987904.63},{"date":"2023-11-24","current":-6.558278,"twenty":-6.982681,"median":-6.613045,"eighty":-6.085918,"marketCap":654468961.83},{"date":"2023-12-01","current":-6.469283,"twenty":-6.777344,"median":-6.486397,"eighty":-6.085918,"marketCap":645658268.08},{"date":"2023-12-08","current":-6.667811,"twenty":-6.729423,"median":-6.558278,"eighty":-6.270755,"marketCap":658292574.17},{"date":"2023-12-15","current":-6.708886,"twenty":-6.708886,"median":-6.565124,"eighty":-6.291292,"marketCap":675019398.57},{"date":"2023-12-22","current":-6.859493,"twenty":-6.749961,"median":-6.585661,"eighty":-6.304984,"marketCap":690021158.62},{"date":"2023-12-29","current":-6.722577,"twenty":-6.78282,"median":-6.609622,"eighty":-6.321414,"marketCap":681416772.26},{"date":"2024-01-05","current":-6.626736,"twenty":-6.777344,"median":-6.626736,"eighty":-6.346059,"marketCap":664561787.4},{"date":"2024-01-12","current":-6.845802,"twenty":-6.796512,"median":-6.667811,"eighty":-6.407671,"marketCap":685854313.55},{"date":"2024-01-19","current":-7.023793,"twenty":-6.859493,"median":-6.681503,"eighty":-6.435054,"marketCap":698334715.34},{"date":"2024-01-26","current":-7.986412,"twenty":-6.982718,"median":-6.681503,"eighty":-6.435054,"marketCap":792063074.67},{"date":"2024-02-02","current":-8.137618,"twenty":-7.092251,"median":-6.715732,"eighty":-6.469283,"marketCap":807847078.54},{"date":"2024-02-09","current":-7.972666,"twenty":-7.379774,"median":-6.743115,"eighty":-6.503512,"marketCap":785337680.3},{"date":"2024-02-16","current":-7.738985,"twenty":-7.738985,"median":-6.763653,"eighty":-6.503512,"marketCap":761909093.06},{"date":"2024-02-23","current":-8.385046,"twenty":-7.788813,"median":-6.78419,"eighty":-6.508989,"marketCap":829978945.38},{"date":"2024-03-01","current":-8.879901,"twenty":-7.848771,"median":-6.818419,"eighty":-6.548694,"marketCap":878391233.38},{"date":"2024-03-08","current":-8.921139,"twenty":-7.986412,"median":-6.859493,"eighty":-6.569232,"marketCap":892211380.33},{"date":"2024-03-15","current":-8.659965,"twenty":-8.228342,"median":-6.982681,"eighty":-6.577447,"marketCap":863166780.31},{"date":"2024-03-22","current":-9.319772,"twenty":-8.319065,"median":-7.010102,"eighty":-6.584292,"marketCap":926107447.06},{"date":"2024-03-28","current":-9.209804,"twenty":-8.585737,"median":-7.078559,"eighty":-6.597984,"marketCap":910336135.23},{"date":"2024-04-05","current":-9.732151,"twenty":-8.736943,"median":-7.311316,"eighty":-6.610307,"marketCap":967400801.65},{"date":"2024-04-12","current":-5.879845,"twenty":-8.706701,"median":-7.078559,"eighty":-6.566493,"marketCap":928230894.29},{"date":"2024-04-19","current":-6.030284,"twenty":-8.692955,"median":-6.99641,"eighty":-6.48982,"marketCap":950004364.47},{"date":"2024-04-26","current":-6.311356,"twenty":-8.670962,"median":-6.941624,"eighty":-6.433272,"marketCap":998864220.67},{"date":"2024-05-03","current":-5.987697,"twenty":-8.585737,"median":-6.859493,"eighty":-6.311356,"marketCap":946423801.22},{"date":"2024-05-10","current":-5.698107,"twenty":-8.470271,"median":-6.80815,"eighty":-6.289097,"marketCap":907055615.77},{"date":"2024-05-17","current":-5.502208,"twenty":-8.401541,"median":-6.777344,"eighty":-6.21545,"marketCap":883582818.48},{"date":"2024-05-24","current":-5.348896,"twenty":-8.33556,"median":-6.749961,"eighty":-6.06538,"marketCap":855336978.03},{"date":"2024-05-31","current":-5.357413,"twenty":-8.297072,"median":-6.736269,"eighty":-6.030284,"marketCap":858278233.57},{"date":"2024-06-07","current":-5.493691,"twenty":-8.288824,"median":-6.708886,"eighty":-5.988933,"marketCap":883175015.23},{"date":"2024-06-14","current":-5.042271,"twenty":-8.277827,"median":-6.681503,"eighty":-5.938296,"marketCap":801878490.85},{"date":"2024-06-21","current":-5.510725,"twenty":-8.253084,"median":-6.681503,"eighty":-5.777439,"marketCap":872433075.44},{"date":"2024-06-28","current":-4.974132,"twenty":-8.244837,"median":-6.681503,"eighty":-5.74004,"marketCap":786723361.52},{"date":"2024-07-05","current":-5.306309,"twenty":-8.203599,"median":-6.667811,"eighty":-5.629968,"marketCap":847517911.35},{"date":"2024-07-12","current":-5.408517,"twenty":-8.118374,"median":-6.619891,"eighty":-5.595899,"marketCap":868631706.71},{"date":"2024-07-15","current":-5.417034,"twenty":-8.099129,"median":-6.613045,"eighty":-5.590788,"marketCap":873513053.92},{"date":"2024-08-02","current":-4.676203,"twenty":-8.079885,"median":-6.609622,"eighty":-5.583974,"marketCap":745105907.03},{"date":"2024-08-09","current":-4.513478,"twenty":-8.008406,"median":-6.578816,"eighty":-5.515836,"marketCap":727494223.22},{"date":"2024-08-16","current":-4.316495,"twenty":-7.986412,"median":-6.534318,"eighty":-5.490284,"marketCap":700482151.8},{"date":"2024-08-23","current":-4.453526,"twenty":-7.978164,"median":-6.503512,"eighty":-5.44429,"marketCap":730827498.61},{"date":"2024-08-30","current":-4.898879,"twenty":-7.906686,"median":-6.449861,"eighty":-5.413627,"marketCap":801684090.61},{"date":"2024-09-06","current":-4.667638,"twenty":-7.862699,"median":-6.432827,"eighty":-5.36082,"marketCap":764519824.83},{"date":"2024-09-13","current":-3.822511,"twenty":-7.855735,"median":-6.332367,"eighty":-5.335268,"marketCap":748409890.75},{"date":"2024-09-20","current":-3.623827,"twenty":-7.841256,"median":-6.30817,"eighty":-5.285867,"marketCap":716147844.73},{"date":"2024-09-27","current":-3.630961,"twenty":-7.835207,"median":-6.291292,"eighty":-5.156403,"marketCap":720043812.45},{"date":"2024-10-04","current":-3.210083,"twenty":-7.830393,"median":-6.281546,"eighty":-4.898879,"marketCap":627325694.46},{"date":"2024-10-11","current":-2.96041,"twenty":-7.805992,"median":-6.132492,"eighty":-4.671064,"marketCap":573856377.14},{"date":"2024-10-18","current":-3.434789,"twenty":-7.774725,"median":-6.075649,"eighty":-4.6094,"marketCap":659899758.53},{"date":"2024-10-25","current":-3.324219,"twenty":-7.75548,"median":-6.033455,"eighty":-4.49121,"marketCap":637070240.87},{"date":"2024-10-31","current":-3.438356,"twenty":-7.738985,"median":-6.030284,"eighty":-4.463804,"marketCap":662378132.46},{"date":"2024-11-08","current":-3.427655,"twenty":-7.738985,"median":-5.993854,"eighty":-4.429546,"marketCap":655972131.38},{"date":"2024-11-15","current":-3.106647,"twenty":-7.711493,"median":-5.970662,"eighty":-4.328485,"marketCap":583153684.93},{"date":"2024-11-22","current":-3.010345,"twenty":-7.590528,"median":-5.940851,"eighty":-3.765459,"marketCap":560275247.04},{"date":"2024-11-29","current":-2.837956,"twenty":-7.546541,"median":-5.882667,"eighty":-3.688029,"marketCap":531199944.09},{"date":"2024-12-06","current":-2.848666,"twenty":-7.379774,"median":-5.732176,"eighty":-3.623827,"marketCap":534218918.72},{"date":"2024-12-13","current":-2.548806,"twenty":-7.311316,"median":-5.65552,"eighty":-3.566759,"marketCap":474325506.61},{"date":"2024-12-20","current":-2.520248,"twenty":-7.311316,"median":-5.604416,"eighty":-3.452623,"marketCap":464239022.01},{"date":"2024-12-27","current":-2.516678,"twenty":-7.267503,"median":-5.595899,"eighty":-3.437643,"marketCap":465029850.03},{"date":"2025-01-03","current":-2.49883,"twenty":-7.157971,"median":-5.578864,"eighty":-3.421948,"marketCap":454676281.41},{"date":"2025-01-10","current":-2.309632,"twenty":-7.081298,"median":-5.52776,"eighty":-3.400548,"marketCap":421851498.87},{"date":"2025-01-17","current":-2.156736,"twenty":-7.048438,"median":-5.506467,"eighty":-3.355607,"marketCap":393925230.6},{"date":"2025-01-24","current":-2.178161,"twenty":-7.018316,"median":-5.493691,"eighty":-3.318513,"marketCap":402353167.1},{"date":"2025-01-31","current":-2.156736,"twenty":-6.993672,"median":-5.459621,"eighty":-3.135894,"marketCap":398893952.88},{"date":"2025-02-07","current":-2.038902,"twenty":-6.982711,"median":-5.442586,"eighty":-3.053859,"marketCap":375339390.95},{"date":"2025-02-14","current":-2.431685,"twenty":-6.966258,"median":-5.417034,"eighty":-3.014625,"marketCap":450591803.66},{"date":"2025-02-21","current":-2.725249,"twenty":-6.900568,"median":-5.408517,"eighty":-2.924742,"marketCap":505993414.61},{"date":"2025-02-28","current":-2.478798,"twenty":-6.859493,"median":-5.361671,"eighty":-2.877224,"marketCap":457649034.34},{"date":"2025-03-07","current":-2.62524,"twenty":-6.859493,"median":-5.348896,"eighty":-2.848666,"marketCap":504421902.75},{"date":"2025-03-14","current":-1.950178,"twenty":-6.845802,"median":-5.331861,"eighty":-2.792772,"marketCap":375893933.73},{"date":"2025-03-21","current":-2.425222,"twenty":-6.818419,"median":-5.306309,"eighty":-2.725249,"marketCap":466899893.66},{"date":"2025-03-28","current":-2.16502,"twenty":-6.797881,"median":-5.23817,"eighty":-2.643099,"marketCap":411881933.29},{"date":"2025-04-04","current":-1.798189,"twenty":-6.791035,"median":-5.118927,"eighty":-2.598783,"marketCap":350804145.45},{"date":"2025-04-11","current":-1.7874,"twenty":-6.777344,"median":-4.936505,"eighty":-2.541667,"marketCap":352326323.68},{"date":"2025-04-17","current":-1.884502,"twenty":-6.777344,"median":-4.813235,"eighty":-2.527388,"marketCap":377676205.37},{"date":"2025-04-25","current":-2.187427,"twenty":-6.755438,"median":-4.676203,"eighty":-2.49883,"marketCap":437738722.61},{"date":"2025-05-02","current":-2.334934,"twenty":-6.749961,"median":-4.641945,"eighty":-2.473083,"marketCap":464043181.1},{"date":"2025-05-09","current":-2.219807,"twenty":-6.744484,"median":-4.599123,"eighty":-2.430392,"marketCap":441113036.42}],"updateTime":1746993279196}}}